Overview
- Jurors found Apple infringed Masimo’s pulse‑oximetry patent and determined certain Apple Watch models qualify as a patient monitor.
- The award covers roughly 43 million devices, after the jury accepted Masimo’s view that features like workout mode and heart‑rate alerts used the patented methods.
- Apple said it will appeal, arguing the patent expired in 2022 and relates to older patient‑monitoring technology.
- Damages were contested, with Apple urging $3–6 million and Masimo seeking $634–$749 million; the jury granted $634 million.
- The ITC has opened a new proceeding to assess Apple’s redesign for potential import restrictions, while Masimo separately challenges CBP’s earlier clearance of the iPhone‑processed blood‑oxygen workaround.